Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Emily Cutshall

Physician Assistant Marlton, NJ Physician Assistant

NPI 1558026153 CMS profile 11372943

777 Route 70 E, Ste G101, Marlton, NJ 08053

Open in the dashboard

General payments

$6,938

436 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Emily Cutshall of Marlton, NJ is reported in the CMS Open Payments database as having received $6,938 across 436 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,130 72
2024 General $2,193 142
2023 General $1,965 135
2022 General $1,650 87

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Emily Cutshall
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Emily Cutshall were reported at $1,130. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Emily Cutshall Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $1,650 $155 $48–$522 $149
2023 $1,965 $167 $52–$557 $160
2024 $2,193 $178 $55–$600 $164
2025 $1,130 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Novo Nordisk Inc $972 66 payments
  2. AbbVie, Inc. $655 50 payments
  3. Amgen Inc. $457 33 payments
  4. Biohaven Pharmaceutical Holding Company Ltd. $450 20 payments
  5. Pfizer Inc. $417 27 payments
  6. Lilly USA, LLC $332 21 payments
  7. AstraZeneca Pharmaceuticals LP $284 19 payments
  8. ITI, Inc. $279 11 payments
  9. Otsuka America Pharmaceutical, Inc. $249 14 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $228 15 payments
  11. Other $2,615 160 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $6,938 436 payments
Products named General payments · program years 2022–2025
  1. RYBELSUS $665 46 payments
  2. Ozempic $605 44 payments
  3. NURTEC ODT Primary Care $450 20 payments
  4. NURTEC ODT Pain $339 22 payments
  5. CAPLYTA $279 11 payments
  6. EVENITY $274 21 payments
  7. QULIPTA $264 21 payments
  8. Prolia $256 20 payments
  9. Wegovy $249 16 payments
  10. REXULTI $249 14 payments
  11. Other $6,481 410 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

436 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record